585 related articles for article (PubMed ID: 32631004)
1. Relationship Between Final Visual Acuity and Optical Coherence Tomography Findings in Patients with Diabetic Macular Edema Undergoing Anti-VEGF Therapy.
Eraslan S; Yıldırım Ö; Dursun Ö; Dinç E; Orekici Temel G
Turk J Ophthalmol; 2020 Jun; 50(3):163-168. PubMed ID: 32631004
[TBL] [Abstract][Full Text] [Related]
2. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG
Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
[TBL] [Abstract][Full Text] [Related]
3. Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity.
Busch C; Okada M; Zur D; Fraser-Bell S; Rodríguez-Valdés PJ; Cebeci Z; Lupidi M; Fung AT; Gabrielle PH; Giancipoli E; Chaikitmongkol V; Laíns I; Santos AR; Kunavisarut P; Sala-Puigdollers A; Chhablani J; Ozimek M; Hilely A; Degenhardt V; Loewenstein A; Iglicki M; Rehak M;
Acta Ophthalmol; 2020 Nov; 98(7):e801-e806. PubMed ID: 32115886
[TBL] [Abstract][Full Text] [Related]
4. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
5. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
[No Abstract] [Full Text] [Related]
6. Disorganization of the Retinal Inner Layers after Anti-VEGF Treatment for Macular Edema due to Branch Retinal Vein Occlusion.
Nakano E; Ota T; Jingami Y; Nakata I; Hayashi H; Yamashiro K
Ophthalmologica; 2018; 240(4):229-234. PubMed ID: 30089307
[TBL] [Abstract][Full Text] [Related]
7. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
[TBL] [Abstract][Full Text] [Related]
8. Disorganization of Inner Retina and Outer Retinal Morphology in Diabetic Macular Edema.
Das R; Spence G; Hogg RE; Stevenson M; Chakravarthy U
JAMA Ophthalmol; 2018 Feb; 136(2):202-208. PubMed ID: 29327033
[TBL] [Abstract][Full Text] [Related]
9. OCT Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema.
Hsieh YT; Alam MN; Le D; Hsiao CC; Yang CH; Chao DL; Yao X
Ophthalmol Retina; 2019 Oct; 3(10):826-834. PubMed ID: 31227330
[TBL] [Abstract][Full Text] [Related]
10. Optical Coherence Tomography Angiography of DME and Its Association with Anti-VEGF Treatment Response.
Lee J; Moon BG; Cho AR; Yoon YH
Ophthalmology; 2016 Nov; 123(11):2368-2375. PubMed ID: 27613201
[TBL] [Abstract][Full Text] [Related]
11. Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections.
Cetin EN; Demirtaş Ö; Özbakış NC; Pekel G
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1801-1806. PubMed ID: 29922890
[TBL] [Abstract][Full Text] [Related]
12. Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features.
Hatz K; Ebneter A; Tuerksever C; Pruente C; Zinkernagel M
Ophthalmologica; 2018; 239(4):205-214. PubMed ID: 29402873
[TBL] [Abstract][Full Text] [Related]
13. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
[TBL] [Abstract][Full Text] [Related]
14. Optical coherence tomography biomarkers DROL, PROS, SND, hyperreflective walls of foveal cystoid spaces as predictors of central macular thickness and visual acuity in diabetic macular edema treated with intravitreal ranibizumab.
Sardana A; Singh K; Singh A; Singh VK
Indian J Ophthalmol; 2024 May; 72(5):722-727. PubMed ID: 38648434
[TBL] [Abstract][Full Text] [Related]
15. Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion.
Yiu G; Welch RJ; Wang Y; Wang Z; Wang PW; Haskova Z
Ophthalmol Retina; 2020 Jan; 4(1):67-76. PubMed ID: 31669329
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema.
Ebneter A; Waldmeier D; Zysset-Burri DC; Wolf S; Zinkernagel MS
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):549-555. PubMed ID: 27714513
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment.
Kaya M; Karahan E; Ozturk T; Kocak N; Kaynak S
Korean J Ophthalmol; 2018 Aug; 32(4):296-302. PubMed ID: 30091308
[TBL] [Abstract][Full Text] [Related]
18. Retinal Layers Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Anti-VEGF Agents: Long-Term Outcomes of a Spectral-Domain OCT Study.
Chatziralli I; Kazantzis D; Theodossiadis G; Theodossiadis P; Sergentanis TN
Ophthalmic Res; 2021; 64(2):230-236. PubMed ID: 32564022
[TBL] [Abstract][Full Text] [Related]
19. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers.
Bonfiglio V; Reibaldi M; Pizzo A; Russo A; Macchi I; Faro G; Avitabile T; Longo A
Acta Ophthalmol; 2019 Jun; 97(4):e540-e544. PubMed ID: 30318792
[TBL] [Abstract][Full Text] [Related]
20. Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment.
Karst SG; Lammer J; Mitsch C; Schober M; Mehta J; Scholda C; Kundi M; Kriechbaum K; Schmidt-Erfurth U
Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):49-58. PubMed ID: 29080915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
